HDAC9 and neoplasm: Resistance to HDAC inhibitors in general is an emerging and active field of research for a number of tumor types (26), although in the context of this study, the potential for the maintenance of an irreversible, highly methylated state is one possibility, as is the loss of specific histone acetyl transferases within these resistant cells.